← Back to Episodes
PODCAST

The FDA Just Quietly Changed the Rules on HRT Warnings

November 5, 2026·8:35·Episode 161

Quick Summary

This episode covers three women's health stories breaking on election day 2026: FDA's quiet removal of black-box warnings from estrogen patches, a congressional demand for ICE data on miscarriages in immigration detention, and what Tuesday night's ballot results mean for reproductive rights access.

The FDA Just Quietly Changed the Rules on HRT Warnings

0:000:00

Key Takeaways

  • ✦The FDA removed black-box warnings about cardiovascular disease, breast cancer, and dementia from three more estrogen patches — without convening an advisory committee or publicly explaining the scientific basis for the decision.
  • ✦Some menopause researchers support updating the warnings as outdated; others are concerned about the lack of transparency in how the FDA made this call.
  • ✦Voters in Nevada, Virginia, Missouri, and Idaho passed or strengthened abortion protections on election night 2026, as part of a broader Democratic wave.
  • ✦Democratic lawmakers are demanding ICE disclose data on miscarriages, stillbirths, and pregnancy-related hospitalizations among immigrants in detention, after the agency admitted it lost count of these incidents between October 2025 and June 2026.
  • ✦The ICE data gap matters for women's health advocates: you cannot assess or fix a problem in medical care for detained women if no one is tracking what's happening to them.

Episode Script

Thanks Toni. We've got a lot to get into today.

Election day 2026, and there is no shortage of women's health news to work through. I want to start with the FDA story, because it's been sitting in my feed for about a week now and I keep turning it over.

Late last month, the FDA announced it was removing black-box warnings from three more estrogen patches used to treat menopause symptoms. Black-box warnings are the most serious kind the FDA puts on a drug label — the ones that say, essentially, there is a real risk here and you need to know about it. The warnings being removed flagged risks of cardiovascular disease, breast cancer, and dementia.

The FDA has now done this for multiple estrogen products over the past several months. And each time, they have not brought the question to an advisory committee — which is the standard process when you're making a significant change to drug labeling. No outside experts publicly reviewing the evidence. No recorded deliberation. Just: the warnings are going away.

When asked about the scientific basis for the decision, the agency gave very little in the way of specifics at the press briefing.

Here's my actual position on this, because I think it's worth being clear: the science on HRT has genuinely shifted. The original black-box warnings came out of the Women's Health Initiative study from the early 2000s, and that study had real design problems. It enrolled women who were, on average, in their early sixties — well past the window when most women start hormone therapy. The doses and formulations were different from what's commonly used today. The field has moved. A lot of menopause specialists have been arguing for years that those warnings were overstating the risks for healthy women who start HRT around the time of menopause.

So the direction the FDA is moving — toward acknowledging that the old warnings didn't reflect the current evidence — is not crazy. That part I can follow.

What I can't follow is doing it this way. Skipping the advisory committee process means the public has no window into how this decision was made. We don't get to see which studies were weighed. We don't know what the agency made of the studies that do still show elevated risks in certain populations. We don't know whether anyone pushed back internally. When a government agency makes consequential decisions about drugs that millions of women use, transparency isn't a nicety. It's the whole mechanism that makes the decision trustworthy.

There are menopause researchers who are genuinely relieved the warnings are being updated — they've been pushing for this for a long time. And there are other researchers and physicians who agree with the direction but are uncomfortable with the process. Those are two separate concerns, and collapsing them into one makes the conversation harder than it needs to be.

If you are on an estrogen patch, or thinking about one, this news does not mean you should change anything without talking to your prescriber. What it does mean is that if you've avoided hormone therapy specifically because of warnings about heart disease or dementia risk, that conversation with your doctor is worth having again, because the label landscape is shifting and there may be more nuance available to you now than there was when you first got that advice. The kind of updated clinical summaries your doctor might look at on a tool like OpenEvidence would reflect this evolving picture. It's worth asking.

There's something else in the news today that is harder to talk about but needs to be in this episode.

A Guardian investigation found that ICE — Immigration and Customs Enforcement — failed to track data on miscarriages, stillbirths, and pregnancy-related hospitalizations among immigrants in its detention facilities between October 2025 and June 2026. The agency, by its own admission, lost count.

Democratic lawmakers have now sent a formal demand that ICE disclose whatever data does exist.

This is not an abstract data problem. If a federal agency is detaining pregnant women and cannot tell you how many of them miscarried or required hospitalization, that is a failure of basic medical oversight. You can't evaluate whether women are getting adequate care if no one is recording what's happening to them. You cannot fix what you are not measuring.

The care conditions in immigration detention have been documented as inadequate for years — multiple inspections, multiple reports, multiple lawsuits. The specific finding here, that the agency simply stopped keeping count of pregnancy-related medical events, is the kind of institutional failure that tends to get described in passive voice, as if it happened on its own. It didn't. Someone decided not to track it, or decided it wasn't a priority to fix when the system broke down. That's a decision. And a congressional demand for the data is exactly the right response.

For women's health advocates, the ask here is narrow and achievable: produce the records that should have existed all along, account for the gap, and fix the tracking system going forward. That's a floor, not a ceiling. But it's a floor that has to hold.

And then there's what happened at the polls last night.

Voters in Nevada, Virginia, Missouri, and Idaho passed or strengthened abortion protections at the state level, as part of what's being described as a broader blue wave in the midterms. Nevada approved a constitutional amendment protecting abortion access through the second trimester. Missouri and Idaho, which had been among the states with the most restrictive bans since the Dobbs decision, saw voters move to roll back or limit those restrictions.

Access to abortion care has been fragmented and uneven since 2022, and state ballot measures have been one of the main ways voters have been able to respond directly — without relying on legislatures that in some states moved faster on restrictions than their constituents wanted. Last night added more states to the column where constitutional protection now exists.

What this means in practice varies a lot by state. Constitutional protection doesn't automatically mean clinics reopen the next day, or that providers who left come back, or that the procedural and logistical barriers built up over years disappear. But it does mean that in those states, access to abortion care through the second trimester cannot be removed by the next legislative session. That's a meaningful floor.

For women in those states who have been navigating around restrictions — traveling, using telehealth across state lines, making decisions in a climate of legal uncertainty — this is a real shift. For states that didn't have anything on the ballot last night, the patchwork is still the patchwork.

The election-night results don't close the chapter on reproductive access, but they do show that when voters get a direct say, they tend to land somewhere that reflects what polling has consistently found: most Americans support some level of abortion access, and many of the most restrictive state laws are well outside where public opinion actually sits.

That gap between what legislatures passed and what voters actually want has been one of the defining features of post-Dobbs reproductive politics. Last night narrowed it in a few places.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.